The historical trajectory of cannabidiol (CBD) represents a profound intersection of organic chemistry, clinical neurology, and evolving global drug policy. For decades, the Cannabis sativa plant was primarily characterized by its psychoactive constituent, delta-9-tetrahydrocannabinol (-THC), while its non-psychoactive counterparts remained largely misunderstood or dismissed as pharmacological “impurities.” The story of CBD is a narrative of delayed discovery, where a compound isolated in 1940 waited nearly eighty years for federal recognition and pharmaceutical validation. This report provides an exhaustive analysis of CBD’s evolution, beginning with its ethnobotanical roots, through the rigorous chemical elucidation of the mid-20th century, and concluding with the modern multi-billion-dollar wellness industry and the emergence of precision medicine.

The Ethnobotanical Foundations of Cannabis Therapy

The medicinal utilization of the Cannabis sativa plant is one of the oldest recorded therapeutic practices in human history, with evidence of its application stretching back over five millennia.¹ The indigenous origins of the plant are localized to Central Asia and the Indian subcontinent, where it was integrated into cultural and medical systems long before the advent of modern pharmacology.² The earliest documented consumption of cannabis for therapeutic purposes is attributed to the Chinese Emperor Shen Nung in approximately 2737 BCE.² Shen Nung, often regarded as the father of Chinese medicine, reportedly brewed cannabis-infused tea to treat a diverse array of ailments, including malaria, rheumatism, and gout.²

The transition of cannabis from an Eastern herbal staple to a subject of Western scientific inquiry occurred in the early 19th century. Sir William Brooke O’Shaughnessy, an Irish physician and researcher serving with the British East India Company, is credited with introducing cannabis to Western medicine in 1839.² O’Shaughnessy’s clinical observations were foundational; he documented the plant’s efficacy in mitigating the symptoms of cholera, particularly vomiting and stomach pain, and explored its utility as an anticonvulsant for infantile seizures.² These early clinical reports provided the first indications of what would later be identified as the pharmacological properties of cannabinoids, specifically the antiemetic and antiepileptic effects that define CBD’s modern clinical profile.²

The Search for the Active Principle: Isolation and Early Chemistry

Despite the long history of botanical use, the chemical identity of the active compounds within cannabis remained elusive well into the 20th century. This delay was primarily due to the unique chemical properties of the plant’s resins. Unlike opium (morphine) or coca leaves (cocaine), which contain alkaloids that easily crystallize into salts, the active constituents of cannabis are non-nitrogenous, oily substances that do not readily crystallize.⁵ This physical property made it nearly impossible for early organic chemists to isolate pure oily substances from a complex oily mixture using the techniques available in the late 19th century.⁵

The quest for the “active principle” of cannabis began in earnest in the late 1800s. In 1896, Wood and his colleagues isolated a compound they named cannabinol (CBN) from a red oil extract of cannabis.¹ CBN was the first of the phytocannabinoids to be isolated, though its structural configuration remained a mystery for several decades. It was not until 1933 that R.S. Cahn elucidated the structure of CBN, which was later synthesized in 1940 by the laboratories of Roger Adams in the United States and Lord Alexander Todd in the United Kingdom.¹

The isolation of cannabidiol (CBD) occurred almost simultaneously in 1940. Roger Adams, a Harvard graduate and iconic organic chemist at the University of Illinois, successfully isolated CBD from “Minnesota wild hemp”.⁴ Adams achieved this by isolating the compound as its bis(3,5-dinitrobenzoate) ester.⁹ Although Adams had successfully separated the molecule, the scientific community did not yet recognize CBD’s isomerism, and Adams himself was initially unsure of the exact chemical nature or pharmacological significance of his discovery.⁴ Around the same time, Alexander Todd (later Lord Todd) independently isolated CBD and CBN from Egyptian hashish.⁷ Lord Todd, who would eventually win the Nobel Prize for his work on nucleotides, was the first to synthesize hydrogenated versions of CBD (-CBD and -CBD) via hydrogenation in 1940.¹⁰

The Mechoulam Breakthrough: Structural Elucidation and Stereochemistry

The isolation of CBD in 1940 did not immediately lead to a detailed understanding of its function. For over twenty years, the absolute configuration and stereochemistry of the molecule remained unknown. This lack of chemical precision prevented the development of controlled clinical trials, as researchers could not be certain they were working with pure substances or specific isomers.¹¹

The breakthrough occurred in the early 1960s at the Hebrew University of Jerusalem, led by Dr. Raphael Mechoulam. Mechoulam noted with surprise that while morphine and cocaine had been chemically resolved over a century prior, the “chemistry of cannabis was not well known”.¹¹ In 1963, Mechoulam and his colleague Yuval Shvo determined the full structure and absolute configuration of CBD.³ One year later, in 1964, Mechoulam and Yehiel Gaoni successfully isolated and elucidated the structure of -tetrahydrocannabinol (THC).¹

This achievement was the “Rosetta Stone” for cannabinoid research. It allowed scientists to differentiate between the psychoactive effects of THC and the non-intoxicating properties of CBD. Mechoulam’s laboratory subsequently synthesized both (±)--THC and (±)-CBD in 1965, followed by the synthesis of the (+) and (-) enantiomers.¹ By detailing the chemical composition of these molecules, Mechoulam provided the necessary foundation for modern pharmacology, proving that CBD shared a similar chemical skeleton with THC but lacked the specific configuration required to induce a psychoactive “high”.³

Cannabinoid	Formula	Year Isolated	Structure Determined	Primary Effect
Cannabinol (CBN)		1896 1	1933 1	Mildly psychoactive/sedative
Cannabidiol (CBD)		1940 4	1963 3	Non-psychoactive/anti-epileptic
-THC		1964 1	1964 4	Psychoactive/intoxicating
Cannabigerol (CBG)		1964 13	1964 13	Non-psychoactive/anti-inflammatory

Pharmacological Distinction and the 1970s Anticonvulsant Research

Once the structures were determined, research shifted toward defining the pharmacological boundaries of each compound. In 1946, Dr. Walter S. Loewe had conducted early behavioral tests on mice and rabbits, noting that while THC induced a “trance-like state” or excitement, CBD produced “no noticeable effects on behavior”.⁴ However, these results were not definitively confirmed until the late 1960s, when Mechoulam and his associates tested pure THC and CBD on primates.⁴ These primate studies confirmed that THC was the molecule responsible for intoxication and sedation, while CBD was non-intoxicating.⁴

The early 1970s marked the first significant era of clinical research into CBD’s anticonvulsant properties. This work was spearheaded by a group of Brazilian researchers led by Professor Elisaldo Carlini. In 1973, Carlini’s group demonstrated preclinical evidence that CBD could prevent seizures in mice and rats.¹⁴ This challenged the prevailing belief that CBD was an “inactive” molecule.¹⁴ Following successful animal trials, the group conducted a landmark double-blind, placebo-controlled clinical trial involving 15 adult participants with refractory (drug-resistant) epilepsy.¹⁴

The trial, which lasted four and a half months and concluded in 1980, yielded remarkable results: only 10% of the participants who received CBD continued to experience generalized epileptic seizures, compared to 90% of the placebo group.¹⁴ Every patient in the CBD arm showed some level of improvement.⁴ Despite the undeniable significance of these findings, the study was largely ignored by the international scientific community for nearly forty years.¹⁴ Professor Mechoulam later remarked that while the results were “very promising,” the legal and social stigma surrounding cannabis during the peak of the global drug war caused a decades-long hiatus in clinical development.⁴

The Impact of Federal Prohibition and the Systematic Suppression of Science

The history of CBD is inextricably linked to the history of the “War on Drugs” and the systematic prohibition of cannabis science in the United States. The 1937 Marijuana Tax Act had already made research difficult, but the passage of the Controlled Substances Act (CSA) in 1970 established an almost insurmountable barrier.³ Under the CSA, marijuana and all its extracts were classified as Schedule I controlled substances, defined as having a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision.¹⁵

This classification created a paradox where researchers needed to prove the medicinal value of CBD to move it out of Schedule I, but the Schedule I designation itself made obtaining the necessary research materials and funding nearly impossible.¹⁸ Throughout the 1970s and 1980s, organizations like the National Organization for the Reform of Marijuana Laws (NORML) filed multiple petitions to reschedule cannabis.¹⁸ In 1988, Administrative Law Judge Francis L. Young famously ruled that cannabis should be reclassified to Schedule II, describing it as “one of the safest therapeutically active substances known to man”.³ However, DEA Administrator John Lawn overruled the judge’s decision in 1989, and the 1972 NORML petition was not officially denied until 1994—twenty-two years after its initial submission.¹⁸

During the 1980s and 1990s, the focus of government-funded research shifted toward the “harms” of cannabis use.¹⁹ This institutional bias meant that researchers like Carlini and Mechoulam, who were documenting the therapeutic potential of CBD, found little support in the United States.⁶ The discovery of the endocannabinoid system in the late 1980s and early 1990s—including the cloning of the CB1 receptor by Lisa Matsuda and the discovery of anandamide by Lumir Hanuš—gradually began to change the scientific consensus, though the legal framework remained rigid.³

The Duality of US Patent 6,630,507: A Legal and Scientific Paradox

In 2003, a significant event occurred that highlighted the contradictory stance of the United States federal government regarding CBD. The Department of Health and Human Services (HHS) was granted U.S. Patent No. 6,630,507, titled “Cannabinoids as Antioxidants and Neuroprotectants”.⁴ This patent, based on research conducted in the late 1990s by scientists at the National Institute of Mental Health (NIMH), explicitly claimed that cannabinoids were effective in the treatment of various oxidation-associated diseases, including Alzheimer’s, Parkinson’s, and stroke.²²

The patent specifically highlighted the benefits of non-psychoactive cannabinoids like CBD, noting that they could be administered in high doses without the toxicity encountered with psychoactive cannabinoids like THC.²² It described CBD as a potent antioxidant, more powerful than vitamin C or vitamin E, with the ability to protect the brain and nervous system from damage due to trauma or ischemic insults.²²

This action was widely viewed as hypocritical.⁴ While the DEA maintained that CBD had “no medical value,” another branch of the government was patenting it for its medical properties.²² This patent became a focal point for medical cannabis activists and eventually served as a legal and scientific bridge for the modern CBD industry. It provided a powerful counter-argument to the Schedule I classification and established a baseline of legitimacy for CBD as a neuroprotective agent.²²

The Charlotte Figi Phenomenon: The Human Face of CBD Legislation

The modern “CBD revolution” began not in a laboratory, but in the newsroom. In 2013, the story of Charlotte Figi, a young girl with a rare and severe form of epilepsy known as Dravet Syndrome, captivated the American public.⁴ Charlotte suffered from as many as 300 seizures per week, a condition that was resistant to all conventional antiepileptic medications.⁴ Her parents, having exhausted all pharmaceutical options, turned to a low-THC/high-CBD strain of cannabis developed by the Stanley Brothers in Colorado.⁴

The results were transformative: Charlotte’s seizures were reduced to approximately two or three per month, almost overnight.⁴ CNN’s chief medical correspondent, Dr. Sanjay Gupta, featured Charlotte’s story in the documentary Weed, marking a pivotal shift in his personal stance on medical marijuana and galvanizing public interest.⁴ This story moved the debate over CBD from the abstract realms of policy and chemistry to a personal, heartbreaking reality.³⁰

The “Charlotte Figi effect” led to a wave of state-level legislative changes. In 2014 and 2015, dozens of states passed “CBD-only” laws, allowing families with children suffering from refractory epilepsy to access low-THC cannabis oil.²⁸ These laws often received bipartisan support, as lawmakers were moved by the testimony of parents who were “medical refugees,” moving their families to Colorado to obtain the strain renamed “Charlotte’s Web” in her honor.²⁸

The Legal Bifurcation: Industrial Hemp vs. Marijuana

As public demand grew, the federal government was forced to address the legal status of CBD. The challenge lay in the source of the compound. CBD can be derived from either high-THC “marijuana” or low-THC “industrial hemp”.¹⁵ The Agricultural Act of 2014 (the “2014 Farm Bill”) provided the first federal carve-out for hemp.¹⁵ It defined industrial hemp as the Cannabis sativa L. plant with a -THC concentration of not more than 0.3% on a dry weight basis.¹⁵

Under the 2014 Farm Bill, state departments of agriculture and universities were authorized to grow hemp for research and pilot programs.³⁴ While this was a major step forward, the DEA continued to argue that any extract from the cannabis plant remained a Schedule I substance.¹⁵ This led to a contentious period where the legal status of CBD was “convoluted,” with the source of the CBD (hemp-derived vs. marijuana-derived) determining its legality.¹⁵

The definitive change occurred with the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”). This legislation officially removed “hemp” from the Controlled Substances Act, reclassifying it as an agricultural commodity rather than a controlled substance.¹⁵ Hemp-derived CBD was effectively legalized at the federal level, provided it met the 0.3% THC threshold.¹⁷ However, the FDA explicitly maintained its authority over the regulation of CBD in food and dietary supplements, creating a new regulatory hurdle for the burgeoning industry.¹⁷

Pharmaceutical Standardization: The FDA Approval of Epidiolex

Parallel to the rise of the artisanal CBD market, the pharmaceutical industry began the process of formal drug development. The primary goal was to create a purified, standardized CBD product that could be rigorously tested for safety and efficacy. In 2018, this process culminated in the FDA approval of Epidiolex, an oral solution containing a purified, plant-derived form of CBD produced by Greenwich Biosciences (a subsidiary of GW Pharmaceuticals).⁹

Epidiolex was approved for the treatment of seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome.³⁹ This approval was based on four pivotal randomized, double-blind, multicenter clinical trials (the GWPCARE 1-4 trials) that demonstrated a significant reduction in seizure frequency.³⁹ Unlike the non-FDA approved CBD oils found in gas stations or health food stores, Epidiolex is a pharmaceutical-grade product, manufactured under strict regulations to ensure it is free of heavy metals, pesticides, and contaminants.⁴¹

The approval of Epidiolex had several historic consequences:

• Federal Reclassification: In September 2018, the DEA placed Epidiolex into Schedule V of the CSA—the least restrictive category—before eventually removing it from all schedules in 2020.⁴²
• Medical Recognition: For the first time, the federal government officially recognized a marijuana-derived compound as having a legitimate medical use, signaling a path forward for other cannabinoid-based therapies.⁴⁰
• Separation of Compounds: Epidiolex helped distinguish CBD from the psychoactive effects of THC in the medical discourse, proving that CBD could provide substantial therapeutic benefit without the “high”.³⁹

The Wellness Boom and the Mainstream Retail Explosion

Following the 2018 Farm Bill, CBD transitioned from a niche medical treatment to a “mainstream wellness” commodity. This shift was fueled by a confluence of factors: increased scientific validation, a consumer shift toward holistic and natural remedies, and the deregulation of hemp.⁴⁴ The appeal of CBD as a health and wellness tool rests on the perception that it is a “more natural, less harmful” replacement for over-the-counter (OTC) drugs and prescription medications.⁴⁶

The modern CBD market is characterized by a “lifestyle” approach. No longer limited to oils and tinctures, CBD is now found in edibles (gummies), topicals (creams/lotions), softgels, beverages, and even pet care products.⁴⁷ Large-scale retailers, seeking to capitalize on the multi-billion-dollar market, began carrying CBD products in 2019. CVS launched a pilot program in 800 stores, quickly followed by Walgreens in 1,500 stores and Rite Aid.⁵⁰ Luxury beauty brands like Sephora and Neiman Marcus also launched curated CBD sections, positioning the compound as a premium ingredient for skincare and relaxation.⁴⁸

Despite this growth, the industry faces persistent challenges. The FDA continues to issue warning letters to firms marketing CBD with unsubstantiated therapeutic claims, such as treating cancer or Alzheimer’s.³⁸ Furthermore, the lack of standardized regulation leads to widespread labeling inaccuracies. A study published in the Journal of the American Medical Association (JAMA) found that 26% of tested non-FDA approved CBD products had less CBD than claimed, while 20% contained detectable levels of THC.⁴¹

The Future of Cannabinoid Science: Mechanisms and Minor Cannabinoids

As CBD has become a household name, the scientific community has deepened its exploration into the compound’s mechanisms of action and the potential of other “minor cannabinoids.” While the exact mechanism of CBD remains partially unknown, recent research has provided significant insights. In May 2024, researchers at the National University of La Plata reported that CBD inhibits the BK (big potassium) channel, which plays a role in the repolarization of the neuronal action potential.⁹ This discovery helps explain the biophysical basis of CBD’s antiepileptic effects.

Furthermore, current research is expanding into other therapeutic areas:

• Heart Health: In April 2023, researchers reported that CBD could attenuate heart injury caused by perfluorooctanesulfonic acid (PFOS) exposure in mouse models by restoring antioxidant capacity and mitochondrial function.⁹
• Oncology: In September 2023, studies showed that CBD could inhibit the proliferation and invasiveness of prostate cancer cells by reducing the expression of cell-cycle proteins and inhibiting the protein kinase AKT.⁹
• Minor Cannabinoids: The market is increasingly exploring minor cannabinoids like Cannabigerol (CBG) for focus and concentration, and Cannabinol (CBN) for sleep, often blended with CBD to leverage the “entourage effect”.¹³

The global CBD industry is projected to reach approximately $22.05 billion by 2030, with a compound annual growth rate (CAGR) of around 15.8%.⁴⁷ The future of the industry will likely be defined by “next-generation” products with enhanced bioavailability and faster onset, as well as a push toward clinical acceptance for conditions like generalized anxiety, chronic pain, and insomnia.⁴⁴

Synthesis and Conclusion

The history of CBD is a testament to the enduring power of natural compounds and the persistent efforts of scientists to unlock their secrets despite significant legal and social resistance. From its origins as a folk remedy in ancient China to its status as a federally legal, pharmaceutical-grade medication in the 21st century, CBD has fundamentally changed our understanding of human physiology and the therapeutic potential of the Cannabis sativa plant.

The core narrative of CBD is one of delayed recognition. The isolation by Roger Adams in 1940 and the structural determination by Raphael Mechoulam in 1963 were milestones that occurred decades before the general public was aware of the compound’s existence. The clinical breakthroughs of the 1970s Brazilian trials were similarly sidelined by the “War on Drugs,” only to be rediscovered in the early 21st century through the desperate efforts of parents and activists.

Today, the dichotomy between the highly regulated, FDA-approved pharmaceutical market (Epidiolex) and the rapidly growing, largely unregulated wellness market (hemp-derived supplements) remains the primary challenge for the industry. As research moves toward personalized dosing and the integration of minor cannabinoids, the legacy of Charlotte Figi and the pioneering work of Raphael Mechoulam continue to guide the evolution of CBD from a “forbidden drug” to a mainstream essential of modern medicine and wellness. The historical trajectory suggests that we are only at the beginning of understanding the full spectrum of CBD’s impact on public health and medical science.

Works cited

1. Cannabinoid pharmacology: the first 66 years – PMC, , https://pmc.ncbi.nlm.nih.gov/articles/PMC1760722/
2. The History Of CBD: A Brief Timeline – Clean Remedies, , https://cleanremedies.com/blogs/cbd-basics/cbd-history
3. CBD History: Ancient Use, Modern Science, and Future Potential, , https://drkerklaan.com/blogs/explore/cbd-history-ancient-use-modern-science-and-future-potential
4. The Modern History of CBD, From Isolation to FDA Recognition …, , https://www.enecta.com/blogs/news/the-modern-history-of-cbd-from-isolation-to-fda-recognition
5. A Brief but Concise History of the Discovery and Elucidation of the Structure of the Major Cannabinoids – MDPI, , https://www.mdpi.com/2813-1851/4/2/10
6. Ancient Therapy Meets Modern-Day Research – The Epilepsy Association, , https://www.epilepsyassociation.com/epilepsyu/ancient-therapy-meets-modern-day-research
7. A Brief but Concise History of the Discovery and Elucidation of the Structure of the Major Cannabinoids – Preprints.org, , https://www.preprints.org/manuscript/202502.2113
8. A historical overview of chemical research on cannabinoids – Lumir Lab, , https://lumirlab.com/publication/a-historical-overview-of-chemical-research-on-cannabinoids/
9. Cannabidiol – American Chemical Society, , https://www.acs.org/molecule-of-the-week/archive/c/cannabidiol.html
10. Alec Todd – Wikipedia, , https://en.wikipedia.org/wiki/Alec_Todd
11. Raphael Mechoulam and the history of cannabis research, , https://www.ilae.org/journals/epigraph/epigraph-vol-21-issue-1-winter-2019/raphael-mechoulam-and-the-history-of-cannabis-research
12. The Health Effects of Cannabis and Cannabinoids – NCBI Bookshelf, , https://www.ncbi.nlm.nih.gov/books/NBK425762/
13. The Scientific History of Cannabinoids – Smithsonian Magazine, , https://www.smithsonianmag.com/science-nature/the-scientific-history-of-cannabinoids-180981561/
14. Fifty years of research on cannabidiol as an anticonvulsant: the …, , https://pmc.ncbi.nlm.nih.gov/articles/PMC10897777/
15. Regulatory Status of Cannabidiol in the United States: A Perspective – PMC, , https://pmc.ncbi.nlm.nih.gov/articles/PMC6154432/
16. The Evolution of Marijuana as a Controlled Substance and the Federal-State Policy Gap – EveryCRSReport.com, , https://www.everycrsreport.com/reports/R44782.html
17. FDA Clarifies Position on CBD After Passage of 2018 Farm Bill – Hall Render, , https://hallrender.com/2019/01/18/fda-clarifies-position-on-cbd-after-passage-of-2018-farm-bill/
18. Effective Public Management – Brookings Institution, , https://www.brookings.edu/wp-content/uploads/2016/06/Ending-the-US-governments-war-on-medical-marijuana-research.pdf
19. The Systematic Prohibition of U.S. Drug Science – Cato Institute, , https://www.cato.org/outside-articles/systematic-prohibition-us-drug-science
20. Challenges and Barriers in Conducting Cannabis Research – NCBI – NIH, , https://www.ncbi.nlm.nih.gov/books/NBK425757/
21. Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature – PMC, , https://pmc.ncbi.nlm.nih.gov/articles/PMC7357058/
22. The Significance of the ‘507 Patent – Medical Marijuana, Inc., , https://medicalmarijuanainc.com/2015/03/23/the-significance-of-the-507-patent/
23. U.S Government Cannabinoids Patent No. 6630507 | KAASS LAW, , https://kaass.law/blog/u-s-government-cannabinoids-patent-no-6630507
24. Patent Hypocrisy with Cannabis – Portland Mercury, , https://www.portlandmercury.com/cannabis/patent-hypocrisy-with-cannabis-18670108/
25. The Patentability of Cannabis – Scully Scott Murphy & Presser PC, , https://www.ssmp.com/patents/the-patentability-of-cannabis/
26. (b) (6) – Regulations.gov, , https://downloads.regulations.gov/FDA-2015-S-0023-0117/content.pdf
27. Weaving Charlotte’s Web: An In-Depth Guide to Cannabidiol – eGrove, , https://egrove.olemiss.edu/cgi/viewcontent.cgi?article=2359&context=hon_thesis
28. Charlotte’s Web (cannabis) – Wikipedia, , https://en.wikipedia.org/wiki/Charlotte%27s_Web_(cannabis)
29. The Story of Charlotte Figi | CBD Origins | Charlotte’s Web – MUV, , https://muvfl.com/post/charlottes-web
30. They tried everything, and nothing worked. Now, women are turning to cannabis for help – KVIA, , https://kvia.com/health/cnn-health/2026/04/19/they-tried-everything-and-nothing-worked-now-women-are-turning-to-cannabis-for-help/
31. 2010 – 2015 – Joseph A. Bondy, PLLC, , https://josephabondy.com/2010-2015
32. Charlotte’s Web (Cannabis) – Encyclopedia.pub, , https://encyclopedia.pub/entry/32432
33. Senate Bill 1030 (2014) – The Florida Senate, , https://www.flsenate.gov/Session/Bill/2014/1030
34. An Overview of Industrial Hemp Law in the United States, , https://digitalcommons.law.udc.edu/cgi/viewcontent.cgi?article=1006&context=udclr
35. Has the DEA Overstepped by Codifying Marijuana Extracts, Including CBD, as Schedule 1 Substances? [Cannabis Industry Alert] – Cozen O’Connor, , https://www.cozen.com/news-resources/publications/2017/has-the-dea-overstepped-by-codifying-marijuana-extracts-including-cbd-as-schedule-1-substances
36. In a blow to CBD, DEA beats back hemp in court—on a technicality – New Hope Network, , https://www.newhope.com/industry-insights/in-a-blow-to-cbd-dea-beats-back-hemp-in-court-on-a-technicality
37. Hemp Production and the 2018 Farm Bill – 07/25/2019 | FDA, , https://www.fda.gov/news-events/congressional-testimony/hemp-production-and-2018-farm-bill-07252019
38. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), , https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
39. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for …, , https://pmc.ncbi.nlm.nih.gov/articles/PMC6938286/
40. FDA Approves First Marijuana-Based Drug to Treat Epilepsy | Seyfarth Shaw LLP, , https://www.seyfarth.com/news-insights/fda-approves-first-marijuana-based-drug-to-treat-epilepsy.html
41. FDA-Approved Seizure Medication | EPIDIOLEX® (cannabidiol), , https://www.epidiolex.com/what-is-epidiolex
42. FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act – DEA.gov, , https://www.dea.gov/press-releases/2018/09/27/fda-approved-drug-epidiolex-placed-schedule-v-controlled-substance-act
43. Hemp Industry Brings Case Against DEA to Clarify DEA’s Hemp Rule | Insights, , https://www.hklaw.com/en/insights/publications/2020/10/hemp-industry-brings-case-against-dea-to-clarify-deas-hemp-rule
44. Decoding the Global Ascent of Cannabidiol: Navigating the Modern Wellness Market, , https://lineplanet.gr/Health/decoding-899-the-global-ascent-of-cannabidiol-navigating-the-modern-wellness-market/
45. The Rise of CBD in the Wellness Industry – Entrepreneur Asia Pacific, , https://apac.entrepreneur.com/lifestyle/the-rise-of-cbd-in-the-wellness-industry/468731
46. Consumers crazy for CBD? Today’s cannabis movement echoes natural market of the 1990s – SmartBrief, , https://www.smartbrief.com/original/consumers-crazy-cbd-todays-cannabis-movement-echoes-natural-market-1990s
47. The Future is Now: CBD Market Trends, Innovations, and the Road to Mai – Nuleaf Naturals, , https://nuleafnaturals.com/blogs/learn/the-future-is-now-cbd-market-trends-innovations-and-the-road-to-mainstream
48. Cannabidiol Market Size And Share | Industry Report, 2033 – Grand View Research, , https://www.grandviewresearch.com/industry-analysis/cannabidiol-cbd-market
49. Revolutionizing Wellness: Navigating the CBD Landscape with Expert Distribution, , https://www.buyusedlockers.com/Case-Studies/revolutionizing-44510-wellness-navigating-the-cbd-landscape-with-expert-distribution/
50. Retailers Selling CBD Products – The Brightfield Blog, , https://blog.brightfieldgroup.com/retailers-enter-cbd
51. 3 big-box drugstore chains rolling out hemp CBD products in 2019 – New Hope Network, , https://www.newhope.com/retailers/3-big-box-drugstore-chains-rolling-out-hemp-cbd-products-in-2019